{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"condition":["","Malignant neoplasm of rectosigmoid junction","Malignant neoplasm of colon","Malignant neoplasm of rectum"],"disease":["","Malignant Neoplasm Of Rectum","Malignant Neoplasm Of Rectosigmoid Junction","Malignant Neoplasm Of Colon"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2430735"],"location":["Germany"],"study_start_month":["3"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Genetic alterations during treatment of oligometastatic colorectal cancer (GATTACA)","description":"Interventions: Group 1: Patients treated in this study receive a local Therapy (Thermal ablation, Brachytherapy, Mikrowaveablation, stereotactical radiation, surgical resection) after there has been a progress while undergoing Chemotherapy. \nThe study will only accompany the intended Treatment, but not influence the chosen methods.\nDuring the study additional blood samples will be taken during routine blood draws to examinate whether changes in free floating DNA will occur after local Therapy.\nPrimary outcome(s): There is a proportionality between the fall of the free-circulating tumor DNA 8 weeks after therapy and 16-72 week interval and the progression free survival and / or overall survival. (Check of the degree of response)\nStudy Design: Allocation: ; Masking: ; Control: ; Assignment: ; Study design purpose: Prognosis","dates":{"creation":"2016-03-15"},"accession":"2430735","cross_references":{"Deutschen Register Klinischer Studien":["DRKS00006294"]}}